Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 2
1992 1
1995 1
1996 3
1997 1
1998 3
2001 1
2002 1
2003 1
2004 1
2006 3
2007 3
2008 4
2010 2
2011 3
2012 1
2013 3
2019 1
2020 1
2024 3
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

40 results

Results by year

Filters applied: . Clear all
Page 1
Études pharmaco-épidémiologiques : quels niveaux de preuve et comment les atteindre ?
Lapeyre-Mestre M, Sapède C, Moore N; les participants à la table ronde N° 5 de Giens XXVIII :; Bilbault P, Blin P, Chopy D, Evans D, Gueyffier F, Lacoin L, Malbezin M, Micallef J, Morlet-Vigier D, Muller S, Oger E, Plétan Y, Pons G, Verpillat P, Vigneau C. Lapeyre-Mestre M, et al. Among authors: pletan y. Therapie. 2013 Jul-Aug;68(4):241-6. doi: 10.2515/therapie/2013037. Therapie. 2013. PMID: 27392726 French. No abstract available.
Modèles de partenariats Public-Privé en France et en Europe.
Demotes-Mainard J, Canet E, Segard L; les participants à la table ronde n° 6 de Giens XXI7. Demotes-Mainard J, et al. Therapie. 2006 Jul-Aug;61(4):313-23. doi: 10.2515/therapie:2006058. Therapie. 2006. PMID: 27393310 French. No abstract available.
Pharmacoepidemiology studies: what levels of evidence and how can they be reached?
Lapeyre-Mestre M, Sapède C, Moore N; participants of round table N° 5 of Giens Workshops XXVIII (th); Bilbault P, Blin P, Chopy D, Evans D, Gueyffier F, Lacoin L, Malbezin M, Micallef J, Morlet-Vigier D, Muller S, Oger E, Plétan Y, Pons G, Verpillat P, Vigneau C. Lapeyre-Mestre M, et al. Among authors: pletan y. Therapie. 2013 Jul-Aug;68(4):241-52. doi: 10.2515/therapie/2013038. Epub 2013 Aug 28. Therapie. 2013. PMID: 23981262 Free article. English, French.
Safety and efficacy of platelet glycoprotein VI inhibition in acute ischaemic stroke (ACTIMIS): a randomised, double-blind, placebo-controlled, phase 1b/2a trial.
Mazighi M, Köhrmann M, Lemmens R, Lyrer PA, Molina CA, Richard S, Toni D, Plétan Y, Sari A, Meilhoc A, Jandrot-Perrus M, Binay S, Avenard G, Comenducci A, Grouin JM, Grotta JC; ACTIMIS Study Group. Mazighi M, et al. Among authors: pletan y. Lancet Neurol. 2024 Feb;23(2):157-167. doi: 10.1016/S1474-4422(23)00427-1. Lancet Neurol. 2024. PMID: 38267188 Clinical Trial.
40 results